Peter Lansbury on Nearly Two Years After FDA Approval, Relyvrio Bombs Phase 3 for ALS
COMMENT This is a huge story. There are many lessons to be learned here. lansburyp_333756 0
SEARCH RESULTS
5 RESULTS
Peter Lansbury on Advisory Committee Again Urges FDA to Vote No on Aducanumab
COMMENT Why doesn't Biogen take the learning from the first two trials and carefully design a trial that can support their contention of efficacy? If they are as certain as their press releases indicate (some of them targeting patients and their families), t
Peter Lansbury on Expression Analysis Uncovers Three Distinct Forms of Alzheimer’s
COMMENT In my opinion, this is the clearest indication that Alzheimer's disease is not a single entity, despite the ubiquity of amyloid plaques, and should not be treated as one. Therapies that seek to slow progression of dementia are unlikely to be effectiv
Peter Lansbury on Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease.
COMMENT This is a beautiful paper showing plaque growth in vivo. I cordially disagree on one point: the authors state that the speed of an individual plaque's growth is surprising because of prior in vitro studies of protein aggregation showing a slow, time-
Peter Lansbury on Zapping Amyloid with SAP Inhibitors
COMMENT This is a beautiful paper that follows a large body of excellent work from these investigators. However, no data is presented as to how the disruption of the interaction between SAP and amyloid fibrils by their drug candidate affects the fate of the amylo